GlassScriptPhysician profile
Salwan P Anton
NPI 1982676433
$16,999.06
in general payments reported to CMS, 2019-2025
44 companies · $2,114 in 2025
The $2,114 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,214 · 2020: $1,246 · 2021: $1,676 · 2022: $1,396 · 2023: $1,533 · 2024: $3,821 · 2025: $2,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,374 · Travel and Lodging: $1,073 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,373.98 |
| Travel and Lodging | $1,073.28 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $4,332.73 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $1,978.00 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Cds - Mct/Cem Monitoring |
| Abbott Laboratories | $1,727.13 | 2019-2025 | Amplatzer Amulet, Ensite Precision, Gallant |
| Janssen Pharmaceuticals, INC | $1,029.51 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $864.43 | 2021-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $744.58 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $561.30 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $507.47 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $454.12 | 2019-2025 | Wainua, Farxiga |
| Amgen INC. | $449.74 | 2019-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $333.22 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.35 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $327.07 | 2020-2025 | Nexletol |
| Scpharmaceuticals INC. | $287.24 | 2024-2025 | |
| Pfizer INC. | $273.18 | 2019-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $270.37 | 2024-2025 | Wegovy, Ozempic |
| Alnylam Pharmaceuticals INC. | $258.36 | 2023-2025 | Onpattro, Amvuttra |
| Amarin Pharma, INC. | $213.36 | 2019-2021 | |
| Lilly USA, LLC | $207.64 | 2024 | Mounjaro, Trulicity |
| Kowa Pharmaceuticals America, INC. | $189.73 | 2019-2021 | |
| Medtronic, INC. | $168.39 | 2021-2025 | Corevalve Evolut R, Closurefast |
| Philips North America LLC | $165.70 | 2022-2025 | Ecc Solutions, (Ck4) Mcot |
| Tactile Systems Technology INC | $156.81 | 2021-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Regeneron Healthcare Solutions, INC. | $148.69 | 2019-2023 | Evkeeza |
| Edwards Lifesciences Corporation | $144.52 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Actelion Pharmaceuticals US, INC. | $120.57 | 2021-2025 | Opsumit, Uptravi |
| Abiomed | $106.09 | 2023-2025 | Impella |
| Kiniksa Pharmaceuticals, LTD. | $95.22 | 2022-2023 | Arcalyst |
| Heartflow, INC. | $75.68 | 2023 | Ffrct |
| Lexicon Pharmaceuticals, INC. | $75.04 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $61.43 | 2024 | Arcalyst |
| Amryt Pharma Holdings LTD | $48.05 | 2020-2022 | |
| Baxter Healthcare | $47.44 | 2023 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Astellas Pharma US INC | $39.93 | 2019-2020 | |
| Glaxosmithkline, LLC. | $31.77 | 2025 | Shingrix |
| Medtronic Vascular, INC. | $29.98 | 2019-2020 | |
| Bridgebio Pharma, INC. | $29.86 | 2025 | Attruby |
| Lundbeck LLC | $28.17 | 2019-2020 | |
| Cordis US Corp. | $22.35 | 2025 | Mynx Control |
| Angiodynamics, INC. | $20.75 | 2021 | |
| Chiesi USA, INC. | $18.57 | 2025 | Juxtapid |
| Daiichi Sankyo INC. | $12.38 | 2021 | |
| Medicomp INC | $12.14 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salwan Anton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.